Search
Research
A randomized, controlled, observer-blind, phase 1/2a study to evaluate the safety, reactogenicity, and immunogenicity of Ad26.RSV.preF in RSV-seronegative toddlers 12 to 24 months of ageJennifer Peter Kent Richmond RN MBBS MRCP(UK) FRACP Clinical Research Manager Head, Vaccine Trials Group Jennifer.Kent@thekids.org.au Clinical
Research
Pertaprime: An investigator-driven phase II-III randomised, observer-blind, controlled trial to demonstrate non-inferior immunogenicity of Pertagen® in comparison to Boostrix® in healthy young Australian adults aged 18-25 yearsJennifer Peter Kent Richmond RN MBBS MRCP(UK) FRACP Clinical Research Manager Head, Vaccine Trials Group Jennifer.Kent@thekids.org.au Clinical
Research
Assessment of on-time vaccination coverage in population subgroups: A record linkage cohort studyOn-time coverage of the 2-4-6 month schedule is only 50-60% across specific population subgroups representing a significant avoidable public health risk
Research
Panel 7 – Pathogenesis of otitis media – A review of the literature between 2015 and 2019The most urgent areas appear to be to continue monitoring the emergence of novel otopathogens, and the need to develop prevention and preventative therapies
Research
Bacterial Reservoirs in the Middle Ear of Otitis-prone Children Are Associated With Repeat Ventilation Tube InsertionPresence of bacterial otopathogen in the middle ear during ventilation tube insertion was a predictor of children at-risk of repeat ventilation tube insertion
Research
Nasal delivery of a commensal Pasteurellaceae species inhibits nontypeable Haemophilus influenzae colonisation and delays onset of otitis media in miceWe have demonstrated that a single dose of a closely related commensal can delay onset of NTHi otitis media in vivo
Research
Evidence of functional cell-mediated immune responses to nontypeable Haemophilus influenzae in otitis-prone childrenThese data provide evidence that otitis-prone children do not have impaired functional cell mediated immunity
Research
Multidrug-resistant tuberculosis in Australia, 1998-2012Multidrug-resistant tuberculosis is uncommon in Australia
Research
4CMenB vaccine and its role in preventing transmission and inducing herd immunityVaccination is the most effective method of protecting people from invasive meningococcal disease (IMD). Of all the capsular groups, B is the most common cause of invasive meningococcal disease in many parts of the world. Despite this, adolescent meningococcal B vaccine programs have not been implemented globally, partly due to the lack of evidence for herd immunity afforded by meningococcal B vaccines.
Research
Meningococcal serogroup B-specific responses after vaccination with bivalent rLP2086Assessment of the persistence of bactericidal antibodies up to 4 years after a three-dose schedule of bivalent rLP2086